The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer.
Jeffrey M Hardacre
No relevant relationships to disclose
Mary Frances Mulcahy
No relevant relationships to disclose
William Small
No relevant relationships to disclose
Mark S. Talamonti
No relevant relationships to disclose
Jennifer Carrie Obel
No relevant relationships to disclose
Caio Max S. Rocha Lima
No relevant relationships to disclose
Howard Safran
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose
E. Gabriela Chiorean
No relevant relationships to disclose
Nicholas N. Vahanian
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Charles J. Link
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics